The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMadeline Fields

About this trial

Ketamine is a medication that came into clinical practice in the 1960's. Ketamine is used as an anesthetic and to provide pain relief. Recently, Ketamine was approved to treat drug resistant depression using subanesthetic doses. In the hospital setting, intravenous anesthetic dosages are used to treat unrelenting seizures known as status epilepticus in comatose patients. Ketamine in subanesthetic doses has not been tried as a treatment for medication resistant seizures in the outpatient setting. This study would like to examine the effectiveness of subanesthetic ketamine in outpatients who suffer from drug resistant epilepsy.

Eligibility criteria

Qualifiers

Provision of signed and dated informed consent form

Adults (18 years or older)

Cognitively impaired adults are not excluded (i.e. will be included in the study)

Established diagnosis of Drug Resistant Epilepsy (DRE) i.e. failed two or more appropriately chosen anti-seizure medications (ASMs)

Disqualifiers

Patients <18 years of age

Pregnant women

Women that are breast feeding

Patients who had >21 days of seizure freedom in the last year.

Trial design

Treatments tested in this trial

  • Ketamine Hydrochloride

Treatment groups

8 Participants
are divided into 1 treatment group

Sponsors and collaborators

Madeline Fields

Lead sponsor

Icahn School of Medicine at Mount Sinai

Sponsor institution